Trial · NCT01065454
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | Mean pulmonary arterial pressure (PAPmean) is a directly measured hemodynamic parameter. PAPmean is recorded during a right heart catheterization. |
| Secondary | Venous Oxygen Saturation (SvO2) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The mixed venous oxygen saturation rate (SvO2) is a directly measured hemodynamic parameter. SvO2 is recorded during a right heart catheterization. |
| Secondary | Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The pulmonary vascular resistance (PVR) is a calculated hemodynamic parameter. PVR is derived from the directly measured parameters mean pulmonary arterial pressure (PAPmean) and pulmonary capillary wedge pressure (PCWP), divided by the cardiac output (CO). PVR and PAPmean are acquired during a right heart catheterization. CO is a calculated hemodynamic parameter, too. Formula: PVR = 80\*(PAPmean - PCWP)/CO |
| Secondary | Pulmonary Vascular Resistance Index (PVRi) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The pulmonary vascular resistance index (PVRi) is a calculated hemodynamic parameter. PVRi is derived from the pulmonary vascular resistance (PVR) normalized by the body surface area (BSA). Formula: PVRi = 80\*(PAPmean - PCWP)\*BSA/CO |
| Secondary | Systemic Vascular Resistance (SVR) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The systemic vascular resistance (SVR) is a calculated hemodynamic parameter. SVR is derived from the directly measured parameter mean right atrial pressure (RAPmean) and the calculated parameter mean systemic arterial pressure (SAPmean) divided by the cardiac output (CO). RAPmean is acquired during a right heart catheterization. CO is a calculated hemodynamic parameter, too. Formula: SVR = 80\*(SAPmean - RAPmean)/CO |
| Secondary | Systemic Vascular Resistance Index (SVRi) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The systemic vascular resistance index (SVRi) is a calculated hemodynamic parameter. SVRi is derived from the systemic vascular resistance (SVR) normalized by the body surface area (BSA). Formula: SVRi = 80\*(SAPmean - RAPmean)\*BSA/CO |
| Secondary | Transpulmonary Pressure Gradient (TPG) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The transpulmonary pressure gradient (TPG) is a calculated hemodynamic parameter. TPG is calculated from the directly measured parameters mean pulmonary arterial pressure (PAPmean) and pulmonary capillary wedge pressure (PCWP). These 2 parameters are acquired during a right heart catheterization. Formula: TPG = PAPmean - PCWP |
| Secondary | Pulmonary Capillary Wedge Pressure (PCWP) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | Pulmonary capillary wedge pressure (PCWP) is a directly measured hemodynamic parameter acquired during a right heart catheterization. |
| Secondary | Tricuspid Annular Plane Systolic Excursion (TAPSE) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The tricuspid annular plane systolic excursion (TAPSE) is a measured echocardiography parameter. It is acquired during a non-invasive echocardiography examination. |
| Secondary | Systolic Pulmonary Arterial Pressure (PAPsyst) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | Systolic pulmonary arterial pressure (PAPsyst) is a directly measured hemodynamic parameter acquired during a right heart catheterization. |
| Secondary | Left Ventricular Ejection Fraction (LVEF) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The left ventricular ejection fraction work index (LVEF) is a calculated echocardiography parameter. LVEF is derived from the directly measured parameters left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). These 2 parameters are acquired during a non-invasive echocardiography examination. Formula: LEVF = 100\*(LVEDV - LVESV)/LVEDV |
| Secondary | Left Ventricular End-systolic Volume (LVESV) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | Left ventricular end-systolic volume (LVESV) is a measured echocardiography parameter. It is acquired during a non-invasive echocardiography examination. |
| Secondary | Left Ventricular End-diastolic Volume (LVEDV) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | Left ventricular end-diastolic volume (LVEDV) is a measured echocardiography parameter. It is acquired during a non-invasive echocardiography examination. |
| Secondary | E-wave Deceleration Time - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | E-wave deceleration time is a measured echocardiography parameter. It is acquired during a non-invasive echocardiography examination. |
| Secondary | Ratio of Mitral Peak Velocity of Early Filling to Mitral Peak Velocity of Late Filling (E/A) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | E/A ratio is a measured echocardiography parameter and describes the ratio of mitral peak velocity of early filling to mitral peak velocity of late filling. It is acquired during a non-invasive echocardiography examination. |
| Secondary | 6-minute Walking Distance (6MWD) - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | 6-minute walking distance (6MWD) is a measure for the objective evaluation of a patient's functional exercise capacity. |
| Secondary | WHO (World Health Organization) Functional Class - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The WHO functional assessment of pulmonary arterial hypertension ranged from functional class I (Patients with PH but without resulting limitation of physical activity) to class IV (Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure.). Changes to a lower WHO functional class resemble improvement, changes to a higher functional class resemble deterioration of PAH. |
| Secondary | Percentage of Participants With Clinical Worsening | At visit 6 (16 weeks) | The combined endpoint "time to clinical worsening", made up of the following components, defined by the first occurrence: all cause mortality, including cardiovascular mortality; first hospitalization for a cardiovascular event, including heart failure, acute myocardial infarction, stroke or ventricular arrhythmia; upgrade of the HTx (heart transplantation) status to next higher level; need for IV diuretics; persistent worsening of WHO functional class due to deterioration of PH or cardiac function. |
| Secondary | Borg CR 10 Scale - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | The Borg CR10 Scale is a patient reported outcome measure used in clinical diagnosis of e.g. breathlessness and dyspnea. It documents the patient's exertion during a physical test. Low values indicate low levels of exertion, high values indicate more intense exertion reported by the patient. The score ranges from 0 ("Nothing at all") to 10 ("Extremely strong - Maximal"). |
| Secondary | EQ-5D Utility Score - Change From Baseline to Week 16 | Baseline and visit 6 (16 weeks) | EQ-5D utility score is a Quality-of-Life patient reported outcome measure. An increase in the utility score represents an improvement in quality of life. The score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01065454/registered